Skip to content
Biotechnology

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

Cambridge Isotope Laboratories, Inc. 2 mins read

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.

OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.

CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.

Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.

Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.

"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."

CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.

About Cambridge Isotope Laboratories, Inc.

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

Contact Information

Crissy Krisko
[email protected]
1.978.269.1930

.

SOURCE: Cambridge Isotope Laboratories, Inc.



View the original press release on accesswire.com

More from this category

  • Biotechnology, Business Company News
  • 19/02/2026
  • 22:53
Ecopha Group Inc

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 19/02/2026
  • 12:50
Q-Sera

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes. Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades,…

  • Biotechnology, Business Company News
  • 12/02/2026
  • 12:22
Jane Morgan Management

BlinkLab Limited (ASX:BB1) Expands Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement

12February 2026 – Sydney, Australia | BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, has expanded its U.S. clinical footprint with the onboarding…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.